High CAR T-Cell Persistence Linked to Severe Gut Complication in Cilta-Cel Myeloma Patients

Researchers at MD Anderson Cancer Center have linked excessively high levels of CAR T-cell persistence to a severe gastrointestinal complication, immune effector cell-associated enterocolitis (IEC-EC), in multiple myeloma patients receiving cilta-cel therapy.

This 2026 finding suggests that the long-term presence of these powerful immune cells drives gut inflammation and tissue damage, prompting new strategies for patient monitoring and drug targeting.

Scientists Investigate Protein Pathways to Manage Immune Overactivity

  • Treatment Strategy: Scientists are now investigating specific protein pathways, like JAK inhibition, to potentially manage this immune overactivity.

Linking CAR T-Cell Persistence to Severe Gut Inflammation

The investigation, published in the journal Nature Medicine, was led by a multidisciplinary team including researchers from The University of Texas MD Anderson Cancer Center. The study focused on patients who received the CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel), a treatment designed to target B-cell maturation antigen (BCMA) in multiple myeloma.

The researchers identified a subset of patients who developed IEC-EC, a rare complication characterized by persistent diarrhea and severe intestinal inflammation. This rare syndrome is not merely gastrointestinal distress; it is recognized as a distinct CAR T-cell therapy-driven immune cell disorder.

In the analysis, which examined 158 patients, the team found that IEC-EC occurred in approximately 5 percent of the treated cohort. Patients who experienced the complication had CAR T cells remaining in their blood at levels more than 100 times higher than those who did not develop the condition. This difference suggests a biological link between prolonged immune activity and tissue damage.

The Cellular Mechanism Driving Mucosal Dysregulation and Tissue Damage

The finding that these cells persist suggests that the treatment’s powerful mechanism of action—the expansion of cytotoxic CAR T cells—can sometimes lead to unintended, long-term immune consequences. Detailed tissue analysis of affected patients revealed that CAR T cells had accumulated within the digestive tract itself. This accumulation appeared to fuel ongoing inflammation and tissue damage.

According to the study, the pathogenesis of IEC-EC involves profound depletion of mucosal B cells and plasma cells, which is accompanied by an expansion of highly cytotoxic CAR-T cells. This cellular imbalance, along with inflammatory remodeling of the stromal and endothelial compartments, is what researchers are now studying to better understand the syndrome. This work helps define CAR-TEC as a multicomponent syndrome of severe mucosal dysregulation.

The team identified specific molecular pathways involved, including interferon and Janus kinase (JAK) signaling. This led them to suggest JAK inhibition, a strategy that has shown promise in managing this toxicity. In fact, the oral selective JAK 1 inhibitor, Upadacitinib, resulted in clinical and endoscopic improvements for two patients with CAR-TEC.

Parameter Patients with IEC-EC (N=10) Control Patients (N=7)
Percentage of Treated Cohort Approximately 5% 0% (by definition)
CAR T-Cell Persistence >100 times average level Baseline levels
Primary Cell Involvement Cytotoxic CAR-T and Inflammatory Myeloid/Stromal cells Compensated mucosal state

Integrating Findings into Global Healthcare Systems

The data, which came from research involving institutions in the United States and Leipzig, Germany, could help clinicians diagnose and treat patients with the complication earlier. By identifying high-persistence levels as a potential risk factor, clinicians may be able to stratify risk, identifying patients who require more intensive, proactive monitoring.

The research from MD Anderson, led by corresponding author Mark Hamilton, suggests that monitoring CAR T-cell levels could be a key predictive measure.

Early Detection Crucial; Endoscopy and Tissue Testing Suggested

Early detection is paramount, as the complication can lead to prolonged hospitalization and increased risk of death. Endoscopic examination of the duodenum, the upper small intestine, along with tissue testing for CAR T cells, are suggested as methods for faster diagnosis.

The researchers at MD Anderson emphasize that while these findings offer crucial insights, further investigation is mandatory. Key questions remain regarding why some patients develop prolonged CAR T-cell persistence and others do not, and how to best prevent the syndrome before it manifests clinically.

MD Anderson Cancer Center, part of the University of Texas System in Houston, was created in 1941 when the Texas Legislature appropriated $500,000 to build a cancer hospital and research center, matched by funds from the MD Anderson Foundation on the condition that the hospital be located in Houston and named after Monroe Dunaway Anderson.

It operated for a decade from surplus World War II Army barracks and leased beds before moving to its permanent home in 1954. Today it is the largest cancer center in the world and one of the original three NCI-designated comprehensive cancer centers in the United States.

The study confirmed that the findings define CAR-TEC as a syndrome of severe mucosal dysregulation that necessitates improved diagnostic protocols. “By understanding the biology behind this complication, we can improve recognition of the syndrome and develop more effective strategies to monitor and treat patients,” Hamilton said.

References

  • Kethidi N, Pothukuchi S, Aleman A et al. Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy. Nature medicine. Published 2026-09-23. https://doi.org/10.1038/s41591-026-04632-y
  • MD Anderson Cancer Center. Research on CAR T-cell persistence and gastrointestinal complications.
  • Newswise. Researchers uncover cause of serious digestive complication after CAR T cell therapy in patients with multiple myeloma.
Photo of author

Health Desk

Health Desk at Archyde.

Pochettino: Man Utd Players Must Relearn ‘About Being Winners